ADMIRAL

Abciximab before Direct Angioplasty & Stenting in Myocardial Infarction Regarding Acute & Long-Term Follow-Up. A trial assessing clinical benefit of abciximab + primary stenting for acute MI
Primary endpoint Composite—death, reinfarction, urgent revascularization of target vessel at 30 days
Conclusion Early abciximab in acute MI improves coronary patency before stenting, stenting success, coronary patency at 6 months, recovery of left ventricular function, outcomes

ADMIRAL

Cardiology A clinical trial–Abciximab before Direct Angioplasty & stenting in Myocardial Infarction Regarding Acute and Long-term followup. See Abciximab, Angioplasty, Myocardial infarction, Stenting.